<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935649</url>
  </required_header>
  <id_info>
    <org_study_id>CLN0001.p.A</org_study_id>
    <nct_id>NCT00935649</nct_id>
  </id_info>
  <brief_title>PinPointe FootLaser for the Treatment of Onychomycosis</brief_title>
  <official_title>Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PathoLase, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PathoLase, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the PathoLase FootLaser treatment of infected
      toenails.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center controlled study evaluating laser treatments of infected great
      toes in a randomized blinded study of approximately 125 subjects. Right and left great toes
      are randomized to treatment or no treatment. Samples from infected areas are sampled and
      evaluated for presence of fungus with KOH, PCR and culture tests. Nail bed clearing and nail
      plate growth are measured from high resolution photographs by a blinded evaluator. Subjects
      will be evaluated at baseline and at 8, 16, 24 and 48 weeks for safety and effectiveness of
      study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nail Bed Clearing</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in amount of clear nail over time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycology</measure>
    <time_frame>48 weeks</time_frame>
    <description>KOH, PCR and cultures of patients who were bilaterally positive or negative for each test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Infected Toenails</condition>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Randomized great toe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with both great toes infected. Right/left randomized to treatment / no treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Toe</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PinPointe FootLaser</intervention_name>
    <description>Medical laser</description>
    <arm_group_label>Randomized great toe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers of either sex,

          -  18-80 years of age,

          -  Both great toes with clinical signs of infection.

          -  Positive KOH or culture test

        Exclusion Criteria:

          -  Existing or history of cancer/skin malignancy,

          -  Use of oral antifungal agents in past 6 months,

          -  Use of topical antifungal agents in past 1 month,

          -  Loss of protective sensation in either foot,

          -  Infection involving lunula of either great toe,

          -  Longitudinal streaks/spikes of either great toenail,

          -  Distal nail thickness &gt; 2 mm of either great toe,

          -  Prior surgical treatment of either great toe in past 12 months,

          -  Participation in another medical device/pharmaceutical study,

          -  Condition that investigator determines makes it unsafe for subject to participate,

          -  Pregnancy, breastfeeding or plans to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Harris, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PathoLase, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Goffe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rochester Laser Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediprobe Research Inc</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <results_first_submitted>April 8, 2013</results_first_submitted>
  <results_first_submitted_qc>April 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <name_title>David M Harris, PhD</name_title>
    <organization>PathoLase, Inc</organization>
  </responsible_party>
  <keyword>Toenail Fungus</keyword>
  <keyword>PinPointe</keyword>
  <keyword>FootLaser</keyword>
  <keyword>Onychomycosis</keyword>
  <keyword>Fungal nails</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Randomized Great Toe</title>
          <description>Subjects with both great toes infected. Right/left randomized to treatment / no treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Great Toe</title>
          <description>Subjects with both great toes infected. Right/left randomized to treatment / no treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nail Bed Clearing</title>
        <description>Change in amount of clear nail over time.</description>
        <time_frame>48 weeks</time_frame>
        <population>There was a fatal design flaw to the trial. We were advised to collect nail samples for mycologic analysis at every visit. As a result investigators were removing our primary outcome variable, increase in clear nail, at each visit. Consequently our estimates of nail growth following treatment are inaccurate and invalid.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Great Toe</title>
            <description>Laser treatment of great toe</description>
          </group>
          <group group_id="O2">
            <title>Untreated Great Toe</title>
            <description>untreated control great toe</description>
          </group>
        </group_list>
        <measure>
          <title>Nail Bed Clearing</title>
          <description>Change in amount of clear nail over time.</description>
          <population>There was a fatal design flaw to the trial. We were advised to collect nail samples for mycologic analysis at every visit. As a result investigators were removing our primary outcome variable, increase in clear nail, at each visit. Consequently our estimates of nail growth following treatment are inaccurate and invalid.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycology</title>
        <description>KOH, PCR and cultures of patients who were bilaterally positive or negative for each test.</description>
        <time_frame>48 weeks</time_frame>
        <population>There was a fatal design flaw to the trial. We were advised to collect nail samples for mycologic analysis at every visit. As a result investigators were removing our primary outcome variable, increase in clear nail, at each visit. Consequently our estimates of nail growth following treatment are inaccurate and invalid.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Great Toe</title>
            <description>Laser treatment of great toe</description>
          </group>
          <group group_id="O2">
            <title>Untreated Great Toe</title>
            <description>untreated control great toe</description>
          </group>
        </group_list>
        <measure>
          <title>Mycology</title>
          <description>KOH, PCR and cultures of patients who were bilaterally positive or negative for each test.</description>
          <population>There was a fatal design flaw to the trial. We were advised to collect nail samples for mycologic analysis at every visit. As a result investigators were removing our primary outcome variable, increase in clear nail, at each visit. Consequently our estimates of nail growth following treatment are inaccurate and invalid.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <desc>Adverse events not assessed for untreated toe. Adverse events are per toe not per patient.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treated Great Toe</title>
          <description>Laser treatment of great toe</description>
        </group>
        <group group_id="E2">
          <title>Untreated Great Toe</title>
          <description>untreated control great toe</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>intraoperative foot pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David M Harris, PhD, Research Director</name_or_title>
      <organization>PathoLase</organization>
      <phone>510-502-3345</phone>
      <email>bmcinc@comcast.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

